Attorneys Author Pharmaceutical Advertising Laws and Regulations 2024 Chapter

A cross-border team of attorneys provided a global analysis of the regulatory compliance landscape on external engagements and communications with healthcare professionals and patients.

In the International Comparative Legal Guide – Pharmaceutical Advertising Laws and Regulations 2024 chapter, the authors explore recent regulatory developments involving scientific and medical communications, including for unapproved uses, historically deemed non-promotional, including scientific communications, as well as how regulators view such communications as impacting promotional issues. The authors also address recent developments in three key geographical regions including the U.S., Europe and Asia related to the regulation of advertising and promotion, especially as it relates to the disclosure of product risks and limitations of promotional claims.

The authors note that there is an overall alignment among the international regulatory authorities as well as the industry trade associations to promote transparency in the clinical trial research process through improved and expanded disclosure of clinical trial data through publicly accessible portals. There is also greater demand by the scientific and medical community as well as patient advocacy groups for objective, unbiased research to be made available to inform individual clinical decisions, systematic reviews, meta-analyzes and development of clinical guidelines.

The chapter was authored by life sciences regulatory & compliance partner and head of European life sciences Lincoln Tsang, life sciences regulatory & compliance partner Kellie Combs and life sciences partner Katherine Wang with contributions from life sciences regulatory & compliance associate Michael Purcell and life sciences associate Jenny Zhang.